Lundbeck - Perform a budget impact analysis for the second class reimbursement submission of a long-acting injectable drug for the maintenance treatment of schizophrenia in Belgium.

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life for people suffering from brain diseases. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at diseases such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.

Project description

Lundbeck asked hict for support in developing a budget impact analysis (BIA) for the reimbursement submission of Abilify Maintena®, a long-acting injectable drug for the maintenance treatment of schizophrenia.

The aim of the project for hict was to provide support for the BIA and the price strategy.

In an intake phase, hict determined the general strategy and the key elements of the BIA: identification of

  • correct comparators;
  • different product values to include in the BIA;
  • requested clinical, epidemiological and cost data for the BIA;
  • current available sources for clinical data, epidemiological data & cost data;
  • possible price strategies.

In the subsequent phase, hict was responsible for

  • data collection & processing of this data;
  • development of the BIA model;
  • population of the model with the collected data;
  • development of a report detailing the BIA and its results.


In the intake phase, based on desk research and literature search, the most appropriate approach and strategy for the BIA in the reimbursement dossier of Abilify Maintena® was defined in cooperation with Lundbeck.

Second, the necessary data collection & processing was done based on desk research. An analysis of the reimbursement criteria of the comparators and existing market researches was performed, together with research on Belgian prevalence data, resource use and unit costs.

Subsequently, the BIA model was developed and populated with the collected Belgian data. A validation of the generated results was performed internally and with Lundbeck.

Finally, an extensive report was written, discussing in detail all aspects of the BIA model, together with the used data, values and sources. The report and the detailed BIA model was delivered and presented to Lundbeck


  • Quantification of all necessary model parameters (prevalence, unit costs, resource use) based on data analysis and literature research;
  • BIA model populated with collected Belgian data (including one-way sensitivity analysis);
  • Detailed report on the model and their final results.

Your contact person

Ann Tanghe
Senior Manager
Ann Tanghe
By submitting this form, you accept the Mollom privacy policy.
Ezelstraat 69 | B- 8000 Brugge | Belgium | Phone: + | Fax: + | BTW BE 0866 039 556 | RPR/RPM Brugge | e-mail: